These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2655343)

  • 1. Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus.
    Piedra PA; Faden HS; Camussi G; Wong DT; Ogra PL
    Vaccine; 1989 Feb; 7(1):34-8. PubMed ID: 2655343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.
    Piedra PA; Wyde PR; Castleman WL; Ambrose MW; Jewell AM; Speelman DJ; Hildreth SW
    Vaccine; 1993 Nov; 11(14):1415-23. PubMed ID: 7508665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of respiratory syncytial virus (RSV) infected cells by in situ hybridization in the lungs of cotton rats immunized with formalin-inactivated virus or purified RSV F and G glycoprotein subunit vaccine and challenged with RSV.
    Murphy BR; Prince GA; Lawrence LA; Croen KD; Collins PL
    Virus Res; 1990 Jun; 16(2):153-62. PubMed ID: 2385958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.
    Connors M; Giese NA; Kulkarni AB; Firestone CY; Morse HC; Murphy BR
    J Virol; 1994 Aug; 68(8):5321-5. PubMed ID: 8035532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.
    Connors M; Kulkarni AB; Firestone CY; Holmes KL; Morse HC; Sotnikov AV; Murphy BR
    J Virol; 1992 Dec; 66(12):7444-51. PubMed ID: 1433525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.
    Prince GA; Jenson AB; Hemming VG; Murphy BR; Walsh EE; Horswood RL; Chanock RM
    J Virol; 1986 Mar; 57(3):721-8. PubMed ID: 2419587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to experimentally induced infection with respiratory syncytial virus: possible role in the development of pulmonary disease.
    Piedra PA; Camussi G; Ogra PL
    J Gen Virol; 1989 Feb; 70 ( Pt 2)():325-33. PubMed ID: 2732693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine.
    Ponnuraj EM; Hayward AR; Raj A; Wilson H; Simoes EAF
    J Gen Virol; 2001 Nov; 82(Pt 11):2663-2674. PubMed ID: 11602778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.
    Sawada A; Nakayama T
    Microbiol Immunol; 2016 Apr; 60(4):234-42. PubMed ID: 26865035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):615-8. PubMed ID: 8322482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV.
    Waris ME; Tsou C; Erdman DD; Day DB; Anderson LJ
    J Virol; 1997 Sep; 71(9):6935-9. PubMed ID: 9261421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus.
    Vaux-Peretz F; Meignier B
    Vaccine; 1990 Dec; 8(6):543-8. PubMed ID: 2087875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.
    Vaux-Peretz F; Chapsal JM; Meignier B
    Vaccine; 1992; 10(2):113-8. PubMed ID: 1539464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.
    Peebles RS; Sheller JR; Collins RD; Jarzecka K; Mitchell DB; Graham BS
    J Infect Dis; 2000 Sep; 182(3):671-7. PubMed ID: 10950758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.